Primary Purposes of our Two Proposed Protocols for Covid19:
Treatment.
Objective: To detect and early diagnose a possible new case of
coronavirus (COVID-19) patient and even healthy carriers, in order to
allow their inclusion in a research protocol with the exclusive use as
single agent, of Clarithromycin 500 mg long acting oral formulation that
allows its administration once a day for 8 days and see if this
treatment per-se is able to reduce and/or disappear the viral load in
that new case or healthy carrier and stop the progression of the disease
to more severe stages, as well as lowering mortality.
Primary Prophylaxis:
Current evidence suggests that person-to-person spreading among
first-line healthcare workers caring for patients suffering from
COVID-19 is a dangerous situation that could leave people without
primary or specialized care and treatment. So far, no drugs or
combinations have been fully recommended, nor are vaccines approved for
the use of antiviral prophylaxis before or after exposure to COVID-19
available, since there is no evidence to support their use yet.
Objective: to test the Clarithromycin 500 mg long acting oral
formulation that allows its administration once a day for 15 days as a
single agent could have a prophylactic effect on members of the health
team directly involved in the care of patients with COVID-19 and highly
exposed to this virus, reducing the possibility of their infection as
well as progression, and permitting to protect themselves.